Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;62(6):4804-4816.
doi: 10.1007/s10528-024-10676-x. Epub 2024 Feb 16.

Occurrence of Existing BCR-ABL Baseline Mutations and Associated Haplotype (NmR) Among CML Patients with Diverse IM Response: A Hospital-based Study from North-East India

Gautam Hazarika  1   2 , Manash Jyoti Kalita  2 , Partha Pratim Das  2   3 , Simanta Kalita  2   4 , Kalpajit Dutta  2 , Lipika Lahkar  5 , Anjanjyoti Rajkonwar  1 , Mohammed Ghaznavi Idris  2 , Vinotsale Khamo  6 , Giriraj Kusre  1 , Subhash Medhi  7
Affiliations

Occurrence of Existing BCR-ABL Baseline Mutations and Associated Haplotype (NmR) Among CML Patients with Diverse IM Response: A Hospital-based Study from North-East India

Gautam Hazarika et al. Biochem Genet. 2024 Dec.

Abstract

Highly polymorphic BCR-ABL kinase domains have been reported to harbor more than a hundred mutations, and among these, 40-60% have been identified as influencers of imatinib mesylate (IM) resistance. The emergence of IM resistance poses a significant challenge in the management of Chronic Myeloid Leukemia (CML). M351T (rs121913457), E255K (rs387906517), and Y253H (rs121913461) are of particular clinical significance due to their association with high-level imatinib resistance. This study was conducted to investigate the potential role of three significant SNPs in CML progression due to IM resistance. During the study period from 2018 to 2022 (48 months), the blood samples from 219 Reverse transcriptase-PCR-confirmed CML patients following RNA extraction and cDNA preparation were subjected to M351T, E255K, and Y253H mutation analysis by PCR-RFLP. After agarose gel visualization, the samples were subjected to Sanger sequencing to confirm the nucleotide change at the polymorphic loci. The wild-type genotype of all three ABL1 SNPs under investigation exhibits a significant reduction in frequency among IM non-responders compared to the responder group. The CGT haplotype frequency exhibits a significant difference between IM responder (4.2%) and non-responder (11.8%) (p = 0.002 < 0.05). Further, CGC haplotype was observed solely among the imatinib non-responder patients with a frequency percentage of 3.3% (p = 0.004), whereas the said genotype was absent among the responder group. A reduced overall survival rate was observed with deviation from wild-type genotype (M351T loci (T > C) with 1.217 times, E255K (G > A) with 1.485 and Y253H (T > C) with 1.399 times increase in hazard ratio) thereby enhancing mortality risk due to disease progression. The significant increase in the frequency of M351T, E255K, and Y253H loci among the IM non-responder group indicated their probable association with the development of IM resistance among CML patients. A haplotype frequency distribution pattern analysis of ABL1 loci further identified the CGC haplotype as an independent predictor for IM resistance. As such the study highlights the importance of patient characteristics, genotype distribution, and haplotype frequency distribution in predicting the response to IM treatment and clinical outcomes of CML patients.

Keywords: E255KG > A; Genotype frequency; Imatinib resistant; M351TT > C; Mutation; RFLP; Y253HT > C.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors have no conflict of interest. Ethical Approval: This study was approved by the Institutional Ethics Committee of Assam Medical College Hospital, Dibrugarh, Assam No AMC/EC/1594 dated 24/7/2020 and Gauhati University Ethics Committee, Guwahati, Assam No: GUIEC/2021/019 dated: 29/9/2021. Consent to Participate: Before taking the blood sample, all the participants of the study (Case/Patients) voluntarily gave their consent for the study. Consent for Publication: The authors have given consent for publication.

Similar articles

See all similar articles

References

    1. Al-Ouqaili MTS, Majeed YH, Al-Ani SK (2020) SEN virus genotype H distribution in β-thalassemic patients and in healthy donors in Iraq: molecular and physiological study. PLoS Negl Trop Dis 14(6):e0007880. https://doi.org/10.1371/journal.pntd.0007880 - DOI - PubMed - PMC
    1. Annamaneni S, Kagita S, Gorre M, Digumarti RR, Satti V, Battini MR (2014) Methylation status of CEBPA gene promoter in chronic myeloid leukemia. Hematology 19(1):42–44. https://doi.org/10.1179/1607845413Y.0000000081 - DOI - PubMed
    1. Bradeen HA, Eide CA, O’Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW (2006) Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations. Blood 108(7):2332–2338. https://doi.org/10.1182/blood-2006-02-004580 - DOI - PubMed - PMC
    1. Corbin AS, Rosée PL, Stoffregen EP, Druker BJ, Deininger MW (2003) Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101(11):4611–4614. https://doi.org/10.1182/blood-2002-12-3659 - DOI - PubMed
    1. de Lavallade H, Kizilors A (2016) The importance of mutational analysis in chronic myeloid leukaemia for treatment choice. EMJ Oncol. https://doi.org/10.33590/emjoncol/10311536 - DOI

LinkOut - more resources